Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2017
At a glance
- Drugs BTI 320 (Primary) ; CD26 antigen inhibitors; Insulins; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Boston Therapeutics
- 26 Apr 2017 According to a Boston Therapeutics media release, recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong (CUHK) . The plans anticipate up to 10 additional institutions from the US and greater China.
- 10 Dec 2014 The US FDA has accepted the IND for this trial, according to a Boston Therapeutics media release.
- 06 May 2014 Status changed from unconfirmed to planning, according to a Boston Therapeutics media release.